Payment overview · 2025
General Payments
$461.57
23 reported records · 12 companies
Healthcare provider profile · identity verified
Garrett N Bennett, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLQUITT, GA · NPI 1336135946
Verified facts
What the public records show
CMS Open Payments records show Garrett N Bennett, MD received $461.57 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ofev by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.56 | 24.2% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.54 | 10.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.39 | 10.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.02 | 8.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.79 | 8.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.27 | 7.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.27 | 6.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.83 | 6.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $26.23 | 5.7% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $24.34 | 5.3% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $15.26 | 3.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.07 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $461.57 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.56 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.13 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.39 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.79 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.88 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 210 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
210 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 592 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 81 |
| Eliquis | Apixaban | 342 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 51 |
| Potassium Chloride | Potassium Chloride | 285 | 50 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 255 | 43 |
| Sodium Chloride | 0.9 % Sodium Chloride | 254 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 38 |
| Farxiga | Dapagliflozin Propanediol | 210 | 24 |
| Lisinopril | Lisinopril | 208 | 37 |
| Levetiracetam | Levetiracetam | 196 | 20 |
| Meloxicam | Meloxicam | 192 | 44 |
| Furosemide | Furosemide | 177 | 39 |
| Losartan Potassium | Losartan Potassium | 177 | 33 |
| Simvastatin | Simvastatin | 174 | 32 |
| Famotidine | Famotidine | 169 | 35 |
| Gabapentin | Gabapentin | 167 | 28 |
| Omeprazole | Omeprazole | 167 | 37 |
| Metformin Hcl | Metformin Hcl | 166 | 28 |
| Sertraline Hcl | Sertraline Hcl | 134 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 23 |
| Baclofen | Baclofen | 126 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 50 |
| Enoxaparin Sodium | Enoxaparin Sodium | 94 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 16 |
| Donepezil Hcl | Donepezil Hcl | 92 | 12 |
| Mupirocin | Mupirocin | 83 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 17 |
| Vancomycin Hcl | Vancomycin Hcl | 78 | 15 |
| Memantine Hcl | Memantine Hcl | 71 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 22 |
| Pregabalin | Pregabalin | 70 | suppressed |
| Carvedilol | Carvedilol | 69 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 14 |
| Entresto | Sacubitril/Valsartan | 68 | 11 |
| Glipizide | Glipizide | 63 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 12 |
| Ozempic | Semaglutide | 61 | 12 |
| Ibuprofen | Ibuprofen | 60 | 24 |
| Midodrine Hcl | Midodrine Hcl | 60 | 19 |
| Allopurinol | Allopurinol | 59 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 58 | suppressed |
| Scopolamine | Scopolamine | 58 | suppressed |
| Lacosamide | Lacosamide | 57 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 55 | suppressed |
| Linzess | Linaclotide | 53 | suppressed |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Jardiance | Empagliflozin | 52 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 52 | 18 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Sodium Chloride | Sodium Chloride 0.45 % | 45 | 11 |
| Unithroid | Levothyroxine Sodium | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | suppressed |
| Lansoprazole | Lansoprazole | 44 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 42 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 41 | 18 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Fentanyl | Fentanyl | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | suppressed |
| Prednisone | Prednisone | 39 | 22 |
| Finasteride | Finasteride | 37 | suppressed |
| Yupelri | Revefenacin | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 19 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 34 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 22 |
| Clonidine | Clonidine | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Sodium Chloride | Sodium Chloride | 30 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 27 | 14 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Magnesium Sulfate | Magnesium Sulfate | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Ertapenem | Ertapenem Sodium | 25 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 15 |
| Cefepime-Dextrose | Cefepime Hcl In Dextrose 5 % | 23 | 18 |
| Dextrose In Water | Dextrose 5 % In Water | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Meropenem | Meropenem | 22 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Novolin R | Insulin Regular, Human | 20 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 20 | suppressed |
| Nystatin | Nystatin | 19 | 13 |
| Prevacid | Lansoprazole | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Brovana | Arformoterol Tartrate | 16 | suppressed |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 16 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Entacapone | Entacapone | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Ofev | Nintedanib Esylate | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $461.57 · 23 records | Novo Nordisk Inc | Auvelity, DAYBUE, Dexcom G6 Transmitter, FARXIGA, Flector, JARDIANCE, Licart, MOUNJARO, NUZYRA, OTEZLA, Ozempic, QULIPTA, QUTENZA, REPATHA, Rybelsus, Tirosint, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error